Roehrborn CG - Search Results

1

Prediction of pathological stage is inaccurate in men with PSA values above 20 ng/mL.

Gallina A, Jeldres C, Chun FK, Shariat SF, Briganti A, Walz J, Roehrborn CG, Saad F, Huland H, Graefen M, Montorsi F, Karakiewicz PI. Gallina A, et al. Among authors: roehrborn cg. Eur Urol. 2007 Nov;52(5):1374-80. doi: 10.1016/j.eururo.2006.12.010. Epub 2006 Dec 11. Eur Urol. 2007. PMID: 17174466

2

Variability of repeated serum prostate-specific antigen (PSA) measurements within less than 90 days in a well-defined patient population.

Roehrborn CG, Pickens GJ, Carmody T 3rd. Roehrborn CG, et al. Urology. 1996 Jan;47(1):59-66. doi: 10.1016/s0090-4295(99)80383-5. Urology. 1996. PMID: 8560664

3

Gleason scores from prostate biopsies obtained with 18-gauge biopsy needles poorly predict Gleason scores of radical prostatectomy specimens.

Djavan B, Kadesky K, Klopukh B, Marberger M, Roehrborn CG. Djavan B, et al. Among authors: roehrborn cg. Eur Urol. 1998;33(3):261-70. doi: 10.1159/000019578. Eur Urol. 1998. PMID: 9555550

4

Neoadjuvant and adjuvant alpha-blockade improves early results of high-energy transurethral microwave thermotherapy for lower urinary tract symptoms of benign prostatic hyperplasia: a randomized, prospective clinical trial.

Djavan B, Shariat S, Fakhari M, Ghawidel K, Seitz C, Partin AW, Roehrborn CG, Marberger M. Djavan B, et al. Among authors: roehrborn cg. Urology. 1999 Feb;53(2):251-9. doi: 10.1016/s0090-4295(98)00538-x. Urology. 1999. PMID: 9933035 Clinical Trial.

5

Prospective randomized comparison of high energy transurethral microwave thermotherapy versus alpha-blocker treatment of patients with benign prostatic hyperplasia.

Djavan B, Roehrborn CG, Shariat S, Ghawidel K, Marberger M. Djavan B, et al. Among authors: roehrborn cg. J Urol. 1999 Jan;161(1):139-43. J Urol. 1999. PMID: 10037386 Clinical Trial.

6

Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia.

Roehrborn CG, Boyle P, Gould AL, Waldstreicher J. Roehrborn CG, et al. Urology. 1999 Mar;53(3):581-9. doi: 10.1016/s0090-4295(98)00655-4. Urology. 1999. PMID: 10096388

7

Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study.

Roehrborn CG, McConnell J, Bonilla J, Rosenblatt S, Hudson PB, Malek GH, Schellhammer PF, Bruskewitz R, Matsumoto AM, Harrison LH, Fuselier HA, Walsh P, Roy J, Andriole G, Resnick M, Waldstreicher J. Roehrborn CG, et al. J Urol. 2000 Jan;163(1):13-20. J Urol. 2000. PMID: 10604304 Clinical Trial.

8

Nadir prostate-specific antigen as a predictor of progression to androgen-independent prostate cancer.

Benaim EA, Pace CM, Lam PM, Roehrborn CG. Benaim EA, et al. Among authors: roehrborn cg. Urology. 2002 Jan;59(1):73-8. doi: 10.1016/s0090-4295(01)01440-6. Urology. 2002. PMID: 11796285

9

Gleason score predicts androgen independent progression after androgen deprivation therapy.

Benaim EA, Pace CM, Roehrborn CG. Benaim EA, et al. Among authors: roehrborn cg. Eur Urol. 2002 Jul;42(1):12-7. doi: 10.1016/s0302-2838(02)00238-5. Eur Urol. 2002. PMID: 12121723

10

Salvage radiotherapy for biochemical failure of radical prostatectomy: a single-institution experience.

Liauw SL, Webster WS, Pistenmaa DA, Roehrborn CG. Liauw SL, et al. Among authors: roehrborn cg. Urology. 2003 Jun;61(6):1204-10. doi: 10.1016/s0090-4295(03)00044-x. Urology. 2003. PMID: 12809898

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

531 results

Search Page